Bang, bang.
From inflammation to pain treatment, RGS, through its Progenza platform, now holds multiple patents in Japan for the use of Mesenchymal Stem Cells.
Then, Sygenus will be added, for the use of stem cells secretions.
Very good news. This will only strengthen Kyocera's commercial position in the Japanese market.
Ann: Regeneus to be granted new patent to target pain in Japan, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.996M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5273 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 4954 | 1 |
View Market Depth
| Last trade - 10.02am 03/09/2024 (20 minute delay) ? |
| CMB (ASX) Chart |
Day chart unavailable